Case number 1:22-cv-00464
Otsuka Pharmaceutical Co., Ltd. et al v. Mylan Laboratories Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 21, 2024 | 311 | REDACTED VERSION of 272 Opening Brief in Support,, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 312 | REDACTED VERSION of 280 Opening Brief in Support, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A and B)(Mayo, Andrew) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 313 | REDACTED VERSION of 291 Answering Brief in Opposition, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 06/21/2024) (13) |
| Jun 21, 2024 | 314 | REDACTED VERSION of 292 Declaration of Jeanette M. Roorda by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A and B)(Mayo, Andrew) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 315 | REDACTED VERSION of 294 Answering Brief in Opposition, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 06/21/2024) (16) |
| Jun 21, 2024 | 316 | REDACTED VERSION of 295 Answering Brief in Opposition, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 06/21/2024) (12) |
| Jun 21, 2024 | 317 | REDACTED VERSION of 296 Declaration, of Jeanette M. Roorda by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A-H)(Mayo, Andrew) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 318 | REDACTED VERSION of 297 Declaration, of Jeanette M. Roorda by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A-I)(Mayo, Andrew) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 319 | REDACTED VERSION of 273 MOTION to Exclude the Testimony of Dr. Byrn as to Statutory-Type Double Patenting by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Text of Proposed Order, # 2 7.1.1 Certification)(Haynes, Christine) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 320 | REDACTED VERSION of 274 Declaration, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1-9)(Haynes, Christine) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 321 | REDACTED VERSION of 275 MOTION to Exclude the Testimony of Dr. Rosenbaum Related to the Exceptions of Section 102(B) by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Text of Proposed Order, # 2 7.1.1 Certification, # 3 Appendix A)(Haynes, Christine) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 322 | REDACTED VERSION of 276 Declaration, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1-4)(Haynes, Christine) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 323 | REDACTED VERSION of 277 MOTION to Exclude the Testimony of Plaintiffs' Experts for Using an Impermissibly Heightened Reasonable Expectation of Success Standard by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Text of Proposed Order, # 2 7.1.1 Certification)(Haynes, Christine) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 324 | REDACTED VERSION of 278 Declaration, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1-8)(Haynes, Christine) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 325 | REDACTED VERSION of 287 Answering Brief in Opposition, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 06/21/2024) (13) |
| Jun 21, 2024 | 326 | REDACTED VERSION of 288 Declaration by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1-13)(Haynes, Christine) (Entered: 06/21/2024) (0) |
| Jun 21, 2024 | 327 | REDACTED VERSION of 289 Answering Brief in Opposition, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 06/21/2024) (13) |
| Jun 21, 2024 | 328 | REDACTED VERSION of 290 Declaration by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1-8)(Haynes, Christine) (Entered: 06/21/2024) (0) |
| Jun 17, 2024 | 310 | SO ORDERED, re 309 Stipulation and Order to Extend Time to File Redacted Versions of Daubert-related Filings to June 21, 2024. Signed by Judge Jennifer L. Hall on 6/17/2024. (ceg) (Entered: 06/17/2024) (2) |
| Jun 14, 2024 | 309 | STIPULATION Seeking to Further Extend the Deadline to File Redacted Public Versions of the Parties' Sealed Daubert Papers, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 06/14/2024) (2) |
| Jun 10, 2024 | 308 | SO ORDERED, re 307 Stipulation and Order to Extend Time to File Redacted Versions of Daubert-related Filings to June 14, 2024. Signed by Judge Jennifer L. Hall on 6/10/2024. (ceg) (Entered: 06/10/2024) (2) |
| Jun 7, 2024 | 306 | ORAL ORDER: The Parties' Joint Motion to Redact Transcript (D.I. 304 ) is DENIED because the statements the parties seek to redact occurred in open court without any party requesting that the teleconference be sealed. See D.I. 103 , Stipulated Protective Order, at 18 ("[A]ny CONFIDENTIAL or HIGHLY CONFIDENTIAL information disclosed in court shall no longer be considered CONFIDENTIAL or HIGHLY CONFIDENTIAL."); Littlejohn v. Bic Corp., 851 F.2d 673, 68081 (3d Cir. 1988). Ordered by Judge Jennifer L. Hall on 6/7/2024. (ceg) (Entered: 06/07/2024) (0) |
| Jun 7, 2024 | 307 | STIPULATION Seeking to Extend the Deadline to File Redacted Public Versions of the Parties' Sealed Daubert Papers, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 06/07/2024) (2) |
| Jun 6, 2024 | 304 | [SEALED] Joint MOTION to Redact 284 Transcript - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A (proposed redactions), # 3 Exhibit B (proposed redactions applied))(Mayo, Andrew) Modified on 6/6/2024 (ceg). (Entered: 06/06/2024) (0) |
| Jun 6, 2024 | 305 | REDACTED VERSION of 304 Joint MOTION to Redact 284 Transcript,, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A, # 3 Exhibit B)(Mayo, Andrew) (Entered: 06/06/2024) (0) |
| May 30, 2024 | 302 | SO ORDERED, re 301 Stipulation of Dismissal without prejudice. (***Civil Case Terminated). Signed by Judge Jennifer L. Hall on 5/30/2024. (ceg) (Entered: 05/30/2024) (2) |
| May 30, 2024 | 303 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,807,680; 8,030,313; 8,338,427; 8,399,469; 8,722,679; 10,525,057; 10,980,803; 11,154,553. (Attachments: # 1 Stipulation of Dismissal)(ceg) (Entered: 05/30/2024) (0) |
| May 28, 2024 | 300 | SO ORDERED, re 299 Stipulation and Order to Extend Time for the parties to file the pretrial order and reply briefs in support of Daubert motions to May 28, 2024. Signed by Judge Jennifer L. Hall on 5/28/2024. (ceg) (Entered: 05/28/2024) (2) |
| May 28, 2024 | 301 | STIPULATION of Dismissal Without Prejudice, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 05/28/2024) (2) |
| May 23, 2024 | 299 | STIPULATION and [Proposed] Order to Extend Time by which the parties must file the Pretrial Order and Reply Briefs in Support of Daubert Motions to May 28, 2024 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Rawnsley, Jason) Modified on 5/23/2024 (ceg). (Entered: 05/23/2024) (2) |
| May 21, 2024 | 298 | SO ORDERED, re 293 Stipulation and Order to Extend Time to File Redacted Versions of Daubert-related Filings and Pre Trial Order to June 7, 2024. Signed by Judge Jennifer L. Hall on 5/21/2024. (ceg) (Entered: 05/21/2024) (2) |
| May 20, 2024 | 286 | NOTICE of Intent to Request Redaction by Andrew Colin Mayo re 284 Transcript,, (Mayo, Andrew) (Entered: 05/20/2024) (2) |
| May 20, 2024 | 287 | [SEALED] ANSWERING BRIEF in Opposition re 271 MOTION to Preclude Certain Testimony of David J. Greenblatt, MD (Motion #1) filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..Reply Brief due date per Local Rules is 5/28/2024. (Haynes, Christine) (Entered: 05/20/2024) (0) |
| May 20, 2024 | 288 | [SEALED] DECLARATION re 287 Answering Brief in Opposition, [Declaration of Emily J. Greb] by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1-13)(Haynes, Christine) (Entered: 05/20/2024) (0) |
| May 20, 2024 | 289 | [SEALED] ANSWERING BRIEF in Opposition re 279 MOTION to Preclude Certain Testimony of Yaning Wang, PH.D. (Motion #2) filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..Reply Brief due date per Local Rules is 5/28/2024. (Haynes, Christine) (Entered: 05/20/2024) (0) |
| May 20, 2024 | 290 | [SEALED] DECLARATION re 289 Answering Brief in Opposition, [Declaration of Emily J. Greb] by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1-8)(Haynes, Christine) (Entered: 05/20/2024) (0) |
| May 20, 2024 | 291 | [SEALED] ANSWERING BRIEF in Opposition re 275 MOTION to Exclude the Testimony of Dr. Rosenbaum Related to the Exceptions of Section 102(B) filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..Reply Brief due date per Local Rules is 5/28/2024. (Balick, Steven) (Entered: 05/20/2024) (0) |
| May 20, 2024 | 292 | [SEALED] DECLARATION re 291 Answering Brief in Opposition, (Declaration of Jeanette M. Roorda) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Balick, Steven) (Entered: 05/20/2024) (0) |
| May 20, 2024 | 293 | STIPULATION TO EXTEND TIME to File Redacted Versions of Daubert-related Filings and Pre Trial Order to June 7, 2024 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 05/20/2024) (2) |
| May 20, 2024 | 294 | [SEALED] ANSWERING BRIEF in Opposition re 273 MOTION to Exclude the Testimony of Dr. Byrn as to Statutory-Type Double Patenting filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..Reply Brief due date per Local Rules is 5/28/2024. (Balick, Steven) (Entered: 05/20/2024) (0) |
| May 20, 2024 | 295 | [SEALED] ANSWERING BRIEF in Opposition re 277 MOTION to Exclude the Testimony of Plaintiffs' Experts for Using an Impermissibly Heightened Reasonable Expectation of Success Standard filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..Reply Brief due date per Local Rules is 5/28/2024. (Balick, Steven) (Entered: 05/20/2024) (0) |
| May 20, 2024 | 296 | [SEALED] DECLARATION re 294 Answering Brief in Opposition, (Declaration of Jeanette M. Roorda) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Balick, Steven) (Entered: 05/20/2024) (0) |
| May 20, 2024 | 297 | [SEALED] DECLARATION re 295 Answering Brief in Opposition, (Declaration of Jeanette M. Roorda) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(Balick, Steven) (Entered: 05/20/2024) (0) |
| May 17, 2024 | 285 | NOTICE OF SERVICE of Defendants' Notice Pursuant to 35 U.S.C. § 282 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 05/17/2024) (2) |
| May 16, 2024 | 281 | MOTION for Pro Hac Vice Appearance of Attorney Laura E. Brashear - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 05/16/2024) (4) |
| May 16, 2024 | 282 | MOTION for Pro Hac Vice Appearance of Attorney Abhinav Garg - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 05/16/2024) (4) |
| May 16, 2024 | 283 | Pro Hac Vice Fee - Credit Card Payment received for Laura E. Brashear and Abhinav Garg. ( re 282 MOTION for Pro Hac Vice Appearance of Attorney Abhinav Garg, 281 MOTION for Pro Hac Vice Appearance of Attorney Laura E. Brashear )( Payment of $ 100, receipt number ADEDC-4409188).(Balick, Steven) (Entered: 05/16/2024) (0) |
| May 16, 2024 | 284 | Official Transcript of Discovery Dispute Teleconference held on 12-08-2023 before Judge Hall. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 6/6/2024. Redacted Transcript Deadline set for 6/17/2024. Release of Transcript Restriction set for 8/14/2024. (Ingram, Stacy) (Entered: 05/16/2024) (0) |
| May 13, 2024 | 271 | MOTION to Preclude Certain Testimony of David J. Greenblatt, MD (Motion #1) - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order)(Balick, Steven) (Entered: 05/13/2024) (0) |
| May 13, 2024 | 272 | [SEALED] OPENING BRIEF in Support re 271 MOTION to Preclude Certain Testimony of David J. Greenblatt, MD (Motion #1) filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..Answering Brief/Response due date per Local Rules is 5/28/2024. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14)(Balick, Steven) (Entered: 05/13/2024) (0) |
| May 13, 2024 | 273 | [SEALED] MOTION to Exclude the Testimony of Dr. Byrn as to Statutory-Type Double Patenting - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Text of Proposed Order, # 2 7.1.1 Certification)(Haynes, Christine) (Entered: 05/13/2024) (0) |
| May 13, 2024 | 274 | [SEALED] DECLARATION re 273 MOTION to Exclude the Testimony of Dr. Byrn as to Statutory-Type Double Patenting [Declaration of Emily J. Greb] by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1-9)(Haynes, Christine) (Entered: 05/13/2024) (0) |
| May 13, 2024 | 275 | [SEALED] MOTION to Exclude the Testimony of Dr. Rosenbaum Related to the Exceptions of Section 102(B) - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Text of Proposed Order, # 2 7.1.1 Certification, # 3 Appendix A)(Haynes, Christine) (Entered: 05/13/2024) (0) |
| May 13, 2024 | 276 | [SEALED] DECLARATION re 275 MOTION to Exclude the Testimony of Dr. Rosenbaum Related to the Exceptions of Section 102(B) [Declaration of Emily J. Greb] by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1-4)(Haynes, Christine) (Entered: 05/13/2024) (0) |
| May 13, 2024 | 277 | [SEALED] MOTION to Exclude the Testimony of Plaintiffs' Experts for Using an Impermissibly Heightened Reasonable Expectation of Success Standard - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Text of Proposed Order, # 2 7.1.1 Certification)(Haynes, Christine) (Entered: 05/13/2024) (0) |
| May 13, 2024 | 278 | [SEALED] DECLARATION re 277 MOTION to Exclude the Testimony of Plaintiffs' Experts for Using an Impermissibly Heightened Reasonable Expectation of Success Standard [Declaration of Emily J. Greb] by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1-8)(Haynes, Christine) (Entered: 05/13/2024) (0) |
| May 13, 2024 | 279 | MOTION to Preclude Certain Testimony of Yaning Wang, PH.D. (Motion #2) - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order)(Balick, Steven) (Entered: 05/13/2024) (0) |
| May 13, 2024 | 280 | [SEALED] OPENING BRIEF in Support re 279 MOTION to Preclude Certain Testimony of Yaning Wang, PH.D. (Motion #2) filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..Answering Brief/Response due date per Local Rules is 5/28/2024. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Balick, Steven) (Entered: 05/13/2024) (0) |
| May 7, 2024 | 270 | NOTICE to Take Deposition of John S. Markowitz, Pharm.D. on May 8, 2024 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 05/07/2024) (2) |
| May 6, 2024 | 267 | NOTICE OF SERVICE of Sur-Reply Expert Report of Andrew Parkinson, Ph.D. filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 05/06/2024) (2) |
| May 6, 2024 | 268 | NOTICE to Take Deposition of Yaning Wang, Ph.D. on May 7, 2024 filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 05/06/2024) (2) |
| May 6, 2024 | 269 | NOTICE to Take Deposition of Stephen R. Byrn, Ph.D. on May 8, 2024 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 05/06/2024) (2) |
| May 1, 2024 | 263 | MOTION for Pro Hac Vice Appearance of Attorney Jeffrey Freeman - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 05/01/2024) (3) |
| May 1, 2024 | 264 | Pro Hac Vice Fee - Credit Card Payment received for Jeffrey Freeman. ( re 263 MOTION for Pro Hac Vice Appearance of Attorney Jeffrey Freeman )( Payment of $ 50, receipt number ADEDC-4396863).(Mayo, Andrew) (Entered: 05/01/2024) (0) |
| May 1, 2024 | 265 | MOTION for Pro Hac Vice Appearance of Attorney Matthew A. Lembo - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 05/01/2024) (3) |
| May 1, 2024 | 266 | Pro Hac Vice Fee - Credit Card Payment received for Matthew A. Lembo. ( re 265 MOTION for Pro Hac Vice Appearance of Attorney Matthew A. Lembo )( Payment of $ 50, receipt number ADEDC-4397579).(Haynes, Christine) (Entered: 05/01/2024) (0) |
| Apr 30, 2024 | 262 | NOTICE to Take Deposition of Gustavo Alva, M.D., DFAPA on May 1, 2024 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 04/30/2024) (2) |
| Apr 29, 2024 | 260 | NOTICE to Take Deposition of Richard F. Bergstrom, Ph.D. on April 30, 2024 filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 04/29/2024) (2) |
| Apr 29, 2024 | 261 | NOTICE to Take Deposition of David J. Greenblatt, M.D. on May 3, 2024 filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 04/29/2024) (2) |
| Apr 25, 2024 | 259 | NOTICE to Take Deposition of Sara E. Rosenbaum, Ph.D. on April 26, 2024 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 04/25/2024) (2) |
| Apr 23, 2024 | 257 | NOTICE to Take Deposition of Andrew Parkinson, Ph.D. on April 24, 2024 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 04/23/2024) (2) |
| Apr 23, 2024 | 258 | NOTICE to Take Deposition of Christopher U. Correll. M.D. on April 24, 2024 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 04/23/2024) (2) |
| Apr 18, 2024 | 256 | NOTICE to Take Deposition of David L. Fogelson, M.D. on April 19, 2024 filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 04/18/2024) (2) |
| Apr 16, 2024 | 255 | NOTICE to Take Deposition of Hugh D. Smyth, Ph.D. on April 18, 2024 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 04/16/2024) (2) |
| Apr 15, 2024 | 254 | NOTICE OF SERVICE of Reply Expert Report of Christoph U. Correll, M.D. filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 04/15/2024) (2) |
| Apr 12, 2024 | 252 | STIPULATION to extend the deadline for the submission of the joint pretrial order, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 04/12/2024) (2) |
| Apr 12, 2024 | 253 | NOTICE OF SERVICE of 1) Expert Report of Dr. Richard F. Bergstrom, Ph.D.; 2) Reply Report of Dr. David Fogelson Regarding Invalidity of the CYP Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,547 & 11,400,087); 3) Reply Expert Report of Dr. Jonathan W. Steed Regarding Invalidity of U.S. Patent No. 8,399,469; 4) Expert Report of Dr. Yaning Wang, Ph.D.; and 5) Reply Report of Dr. David J. Greenblatt Regarding Invalidity of the CYP Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,547 & 11,400,087) filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 04/12/2024) (2) |
| Apr 8, 2024 | 250 | MOTION for Pro Hac Vice Appearance of Attorney Autumn N. Nero - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 04/08/2024) (3) |
| Apr 8, 2024 | 251 | Pro Hac Vice Fee - Credit Card Payment received for Autumn N. Nero. ( re 250 MOTION for Pro Hac Vice Appearance of Attorney Autumn N. Nero )( Payment of $ 50, receipt number ADEDC-4379650).(Haynes, Christine) (Entered: 04/08/2024) (0) |
| Apr 2, 2024 | 249 | STIPULATION and [Proposed] Order Regarding Adjustment to the Case Schedule, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Haynes, Christine) Modified on 4/2/2024 (ceg). (Entered: 04/02/2024) (3) |
| Apr 1, 2024 | 248 | NOTICE OF SERVICE of Final Election of Asserted Claims filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 04/01/2024) (2) |
| Mar 21, 2024 | 245 | REDACTED VERSION of 227 Letter, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Moore, David) (Entered: 03/21/2024) (11) |
| Mar 21, 2024 | 246 | REDACTED VERSION of 228 Exhibit to a Document, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit A1-A4, # 2 Exhibit B1-B4, # 3 Exhibit C1-C2, # 4 Exhibit C3-C12 Part 1, # 5 Exhibit C3-C12 Part 2, # 6 Exhibit C13-C19, # 7 Exhibit D1-D25, # 8 Exhibit E1-E15, # 9 Exhibit F1-F3, # 10 Exhibit G1-G2)(Moore, David) (Entered: 03/21/2024) (0) |
| Mar 21, 2024 | 247 | Letter to The Honorable Jennifer L. Hall from Andrew C. Mayo regarding redactions to Mylan's February 22, 2024 letter and related exhibits. (Attachments: # 1 Exhibit 1)(Mayo, Andrew) (Entered: 03/21/2024) (0) |
| Mar 19, 2024 | 244 | REDACTED VERSION of 229 Letter, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit P1 (part 1 of 2), # 2 Exhibit P1 (part 2 of 2), # 3 Exhibit P2, # 4 Exhibit P3)(Mayo, Andrew) (Entered: 03/19/2024) (0) |
| Mar 18, 2024 | 243 | NOTICE OF SERVICE of (1) Rebuttal Expert Report of Hugh D. Smyth, Ph.D., (2) Rebuttal Expert Report of Gustavo Alva, M.D., DFAPA, (3) Rebuttal Expert Report of Christoph U. Correll, M.D., (4) Rebuttal Expert Report of Stephen R. Byrn, Ph.D., (5) Rebuttal Expert Report of Sara E. Rosenbaum, Ph.D., (6) Rebuttal Expert Report of John S. Markowitz, Pharm. D., and (7) Rebuttal Expert Report of Andrew Parkinson, Ph.D. filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 03/18/2024) (2) |
| Mar 15, 2024 | 241 | SO ORDERED, re 239 Stipulation and Order to Extend Time for Defendants to file redacted public versions of D.I. 227 and 228 to March 21, 2024. Signed by Judge Jennifer L. Hall on 3/15/2024. (ceg) (Entered: 03/15/2024) (2) |
| Mar 15, 2024 | 242 | NOTICE OF SERVICE of Rebuttal Report of Dr. David Fogelson Regarding Non-Infringement of U.S. Patent No. 11,344,547 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 03/15/2024) (2) |
| Mar 14, 2024 | 239 | STIPULATION to extend deadline to file redactions to March 21, 2024, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 03/14/2024) (2) |
| Mar 14, 2024 | 240 | NOTICE OF SERVICE of Final Election of Asserted Prior Art filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 03/14/2024) (2) |
| Mar 11, 2024 | 238 | REDACTED VERSION of 229 Letter, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit P1, # 2 Exhibit P2, # 3 Exhibit P3)(Mayo, Andrew) (Entered: 03/11/2024) (0) |
| Mar 8, 2024 | 237 | SO ORDERED, re 236 Stipulation and Order to Extend Time for Defendants to file redacted public versions of D.I. 227 and 228 to March 14, 2024. Signed by Judge Jennifer L. Hall on 3/8/2024. (ceg) (Entered: 03/08/2024) (2) |
| Mar 7, 2024 | 236 | STIPULATION TO EXTEND TIME for Defendants to file redacted public versions of D.I. 227 and 228 to March 14, 2024 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Moshos, Andrew) (Entered: 03/07/2024) (2) |
| Mar 5, 2024 | 235 | SO ORDERED, re 234 Stipulation and Order for Extension of Time to File Redacted Public Versions of Plaintiffs' February 26, 2024 Letter and Supporting Exhibits (D.I. 229) to March 11, 2024. Signed by Judge Jennifer L. Hall on 3/5/2024. (ceg) (Entered: 03/05/2024) (2) |
| Mar 4, 2024 | 234 | STIPULATION and [Proposed] Order for Extension of Time to File Redacted Public Versions of Plaintiffs' February 26, 2024 Letter and Supporting Exhibits (D.I. 229) to March 11, 2024 by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. (Balick, Steven) Modified on 3/5/2024 (ceg). (Entered: 03/04/2024) (2) |
| Feb 29, 2024 | 232 | STIPULATION TO EXTEND TIME for Defendants to file redacted public versions of D.I. 227 and 228 to March 7, 2024 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Moshos, Andrew) (Entered: 02/29/2024) (2) |
| Feb 29, 2024 | 233 | SO ORDERED, re 232 Stipulation and Order for Defendants to file redacted public versions of D.I. 227 and 228 to March 7, 2024. Signed by Judge Jennifer L. Hall on 2/29/2024. (ceg) (Entered: 02/29/2024) (2) |
| Feb 27, 2024 | 230 | Letter to The Honorable Jennifer L. Hall from David E. Moore regarding enclosure of flash drive containing digital hyperlinked version of Defendants' sealed submissions. (Moore, David) Modified on 2/27/2024 (ceg). (Entered: 02/27/2024) (1) |
| Feb 27, 2024 | 231 | ORAL ORDER: Having reviewed the parties' discovery motions and letters (D.I. 225 , 227 , 228 , 229 ), IT IS HEREBY ORDERED that Defendants' request for leave to amend is DENIED. The parties agree that because the deadline to amend pleadings lapsed in May 2023, Defendants must establish good cause under Fed. R. Civ. P. 16(b)(4). Although it is a close call, the Court is not persuaded that Defendants acted diligently in seeking leave to amend in these circumstances, particularly since (i) Defendants had knowledge of the "FDA Review" document back in April 2023, (ii) the relevant depositions occurred over 3 months ago, and (iii) Defendants told the Court at least as early as early-December 2023 that the then-discovered facts suggested "improper inventorship[] and potential inequitable conduct defenses" (D.I. 197 at 1; see also Dec. 8. 2023 Hrg. Tr. at 21-22). IT IS FURTHER ORDERED that Plaintiffs' motion to strike is DENIED, as most of the information Plaintiffs seek to strike is relevant to a claim/defense in the case. IT IS FURTHER ORDERED that Defendants' motion to compel is DENIED. IT IS FURTHER ORDERED that the teleconference scheduled for tomorrow is CANCELLED. Ordered by Judge Jennifer L. Hall on 2/27/2024. (ceg) (Entered: 02/27/2024) (0) |
| Feb 26, 2024 | 229 | [SEALED] Letter to The Honorable Jennifer L. Hall from Steven J. Balick regarding Plaintiffs' Brief in Opposition to Defendants' Motion to Amend, in Opposition to Defendants' Motion to Compel, and in Support of Plaintiffs' Motion to Strike. (Attachments: # 1 Exhibit P1, # 2 Exhibit P2, # 3 Exhibit P3)(Balick, Steven) (Entered: 02/26/2024) (0) |
| Feb 22, 2024 | 227 | [SEALED] Letter to Honorable Jennifer L. Hall from David E. Moore regarding Brief in Support of Proposed Order to Strike, Compel, and Amend. (Attachments: # 1 Text of Proposed Order - to Strike, # 2 Text of Proposed Order - to Compel, # 3 Text of Proposed Order - to Amend)(Moore, David) Modified on 2/23/2024 (ceg). (Entered: 02/22/2024) (0) |
| Feb 22, 2024 | 228 | [SEALED] EXHIBIT re 227 Letter, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit A1-A4, # 2 Exhibit B1-B4, # 3 Exhibit C1-C6, # 4 Exhibit C7-C14 Pt. 1, # 5 Exhibit C7-C14 Pt. 2, # 6 Exhibit C7-C14 Pt. 3, # 7 Exhibit C15-C19, # 8 Exhibit D1- D11, # 9 Exhibit D12-D22, # 10 Exhibit D23-D25, # 11 Exhibit E1-E15, # 12 Exhibit F1-F3, # 13 Exhibit G1-G2)(Moore, David) (Entered: 02/22/2024) (0) |
| Feb 21, 2024 | 226 | ORAL ORDER Setting Teleconference: The Court has reviewed the Joint Motion for Teleconference to Resolve Discovery Disputes (D.I. 225 ). A discovery dispute teleconference is scheduled for February 28, 2024 at 1:30 PM Eastern Time before Judge Jennifer L. Hall. The Court will accept one 3-page letter brief from each side. Defendants' letter shall be due on February 22, 2024. Plaintiffs' letter shall be due on February 26, 2024. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Jennifer L. Hall on 2/21/2024. (ceg) (Entered: 02/21/2024) (0) |
| Feb 16, 2024 | 225 | Joint MOTION for Teleconference to Resolve Discovery Disputes - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 02/16/2024) (3) |
| Feb 15, 2024 | 224 | CLAIM CONSTRUCTION ORDER. Signed by Judge Jennifer L. Hall on 2/15/2024. (ceg) (Entered: 02/15/2024) (5) |
| Feb 14, 2024 | 223 | PROPOSED Claim Construction Order by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. (Mayo, Andrew) Modified on 2/14/2024 (ceg). (Entered: 02/14/2024) (5) |
| Feb 13, 2024 | 221 | NOTICE OF SERVICE of Opening Expert Report of Christoph U. Correll, M.D., Opening Expert Report of Stephen R. Byrn, Ph.D., and Expert Report of Gustavo Alva, M.D., DFAPA filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 02/13/2024) (2) |
| Feb 13, 2024 | 222 | NOTICE OF SERVICE of Opening Report of Dr. David J. Greenblatt Regarding Invalidity of The Cyp Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,547 & 11,400,087) [Highly Confidential], Expert Report of Nicholas P. Godici [Highly Confidential], Opening Expert Report of Dr. Jonathan W. Steed Regarding Invalidity of U.S. Patent No. 8,399,469 [Highly Confidential], and Opening Report of Dr. David Fogelson Regarding Invalidity of The Cyp Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,547 & 11,400,087) filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Moore, David) (Entered: 02/13/2024) (2) |
| Feb 9, 2024 | 219 | NOTICE OF SERVICE of Corrected Defendants' Second Amended Invalidity Contentions with Exhibits A-F [Highly Confidential Information - Subject to Protective Order] filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Moore, David) (Entered: 02/09/2024) (2) |
| Feb 9, 2024 | 220 | ORAL ORDER: On or before February 14, 2024, the parties are to prepare and file a Claim Construction Order with the constructions set forth in D.I. 144 (see D.I. 213). Ordered by Judge Jennifer L. Hall on 2/9/2024. (ceg) (Entered: 02/09/2024) (0) |
| Feb 2, 2024 | 218 | NOTICE OF SERVICE of Plaintiffs' Second Amended Validity Contentions filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 02/02/2024) (2) |
| Jan 30, 2024 | 214 | NOTICE of Appearance by David Ellis Moore on behalf of Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Pharmaceuticals Inc. (Moore, David) (Entered: 01/30/2024) (2) |
| Jan 30, 2024 | 215 | NOTICE of Appearance by Bindu Ann George Palapura on behalf of Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Pharmaceuticals Inc. (Palapura, Bindu) (Entered: 01/30/2024) (2) |
| Jan 30, 2024 | 216 | NOTICE of Appearance by Andrew Mark Moshos on behalf of Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Pharmaceuticals Inc. (Moshos, Andrew) (Entered: 01/30/2024) (2) |
| Jan 30, 2024 | 217 | NOTICE OF SERVICE of Defendants' Second Amended Invalidity Contentions [Highly Confidential Information-Subject to Protective Order] filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Moore, David) (Entered: 01/30/2024) (2) |
| Jan 22, 2024 | 213 | ORDER: IT IS HEREBY ORDERED that the disputed claim terms shall be construed as set forth in D.I. 144 . The parties shall prepare and file a Claim Construction Order for the Court's signature that sets forth those constructions. To the extent it is necessary, Defendants' Objections (D.I. 152 ) are OVERRULED. Signed by Judge Jennifer L. Hall on 1/22/2024. (ceg) (Entered: 01/22/2024) (2) |
| Jan 11, 2024 | 212 | NOTICE to Take Deposition of Suresh R. Mallikaarjun on January 12, 2024 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 01/11/2024) (2) |
| Dec 28, 2023 | 211 | SO ORDERED, 209 Stipulated Order Adjusting Case Schedule. (*Reset Scheduling Order Deadlines: Opening Expert Reports due by 2/9/2024: Rebuttal Expert Reports due by 3/15/2024; Reply Expert Reports due by 4/5/2024; Expert Discovery due by 5/3/2024; Daubert Motions to be filed by 5/10/2024; Proposed Pretrial Order due by 5/13/2024; A Final Pretrial Conference is set for 6/4/2024 at 03:00 PM in Courtroom 6D before Judge Jennifer L. Hall; A Bench Trial is set for 6/17/2024 at 09:30 AM in Courtroom 6D before Judge Jennifer L. Hall. Signed by Judge Jennifer L. Hall on 12/28/2023. (ceg) (Entered: 12/28/2023) (3) |
| Dec 27, 2023 | 210 | CONSENT to Jurisdiction by U.S. Magistrate Judge filed by H. Lundbeck A/S, Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., Viatris Inc. Case reassigned to Magistrate Judge Jennifer L. Hall. Signed by Judge Colm F. Connolly on 12/27/2023. (nmf) (Entered: 12/27/2023) (3) |
| Dec 22, 2023 | 209 | STIPULATION Regarding Adjustments to Case Schedule and Consent to Jurisdiction of Magistrate Judge, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 12/22/2023) (3) |
| Dec 20, 2023 | 208 | NOTICE of Subpoenas Ad Testificandum on Suresh R. Mallikaarjun, David Goldberger and Jurgen Venitz, M.D., Ph.D. by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Haynes, Christine) (Entered: 12/20/2023) (0) |
| Dec 18, 2023 | 206 | REDACTED VERSION of 196 Letter, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K)(Mayo, Andrew) (Entered: 12/18/2023) (0) |
| Dec 18, 2023 | 207 | REDACTED VERSION of 198 Letter, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A-J)(Mayo, Andrew) (Entered: 12/18/2023) (0) |
| Dec 15, 2023 | 204 | REDACTED VERSION of 197 Letter, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Haynes, Christine) (Entered: 12/15/2023) (0) |
| Dec 15, 2023 | 205 | REDACTED VERSION of 199 Letter,, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 22, # 2 Exhibit 23, # 3 Exhibit 24, # 4 Exhibit 25, # 5 Exhibit 26, # 6 Exhibit 27, # 7 Exhibit 28, # 8 Exhibit 29)(Haynes, Christine) (Entered: 12/15/2023) (0) |
| Dec 14, 2023 | 203 | STIPULATION and [Proposed] Order Extending Expert Report Deadline by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Haynes, Christine) Modified on 12/15/2023 (ceg). (Entered: 12/14/2023) (3) |
| Dec 12, 2023 | 202 | STIPULATION Seeking Extension for the Parties to File Redacted Versions of D.I 196, D.I 197, D.I 198, D.I 199 to December 15, 2023, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 12/12/2023) (2) |
| Dec 8, 2023 | 201 | ORAL ORDER: The Parties' Discovery Motions (D.I. 193 ) are GRANTED-IN-PART and DENIED-IN-PART as stated at today's teleconference. Ordered by Judge Jennifer L. Hall on 12/8/2023. (ceg) (Entered: 12/08/2023) (0) |
| Dec 7, 2023 | 200 | REDACTED VERSION of 193 Joint MOTION for Teleconference to Resolve Discovery Disputes by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 12/07/2023) (3) |
| Dec 6, 2023 | 198 | [SEALED] Letter to The Honorable Jennifer L. Hall from Andrew C. Mayo regarding Plaintiffs' response to Defendants' December 5, 2023 letter - re 197 Letter,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J)(Mayo, Andrew) (Entered: 12/06/2023) (0) |
| Dec 6, 2023 | 199 | [SEALED] Letter to The Honorable Jennifer L. Hall from Frederick L. Cottrell, III regarding in Response to Plaintiffs' December 5, 2023 Letter - re 196 Letter,. (Attachments: # 1 Exhibit 14, # 2 Exhibit 15, # 3 Exhibit 16, # 4 Exhibit 17, # 5 Exhibit 18, # 6 Exhibit 19, # 7 Exhibit 22, # 8 Exhibit 23, # 9 Exhibit 24, # 10 Exhibit 25, # 11 Exhibit 26, # 12 Exhibit 27, # 13 Exhibit 28, # 14 Exhibit 29, # 15 Exhibit 30, # 16 Exhibit 31, # 17 Exhibit 32)(Cottrell, Frederick) (Entered: 12/06/2023) (0) |
| Dec 5, 2023 | 196 | [SEALED] Letter to The Honorable Jennifer L. Hall from Andrew C. Mayo regarding December 8, 2023 Discovery Teleconference to Address Plaintiffs' Request for Assistance Resolving Disputes Concerning Noticed Depositions. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K)(Mayo, Andrew) (Entered: 12/05/2023) (0) |
| Dec 5, 2023 | 197 | [SEALED] Letter to The Honorable Jennifer L. Hall from Frederick L. Cottrell, III regarding discovery disputes. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Cottrell, Frederick) Modified on 12/6/2023 (ceg). (Entered: 12/05/2023) (0) |
| Dec 4, 2023 | 195 | ORAL ORDER Setting Teleconference: The Court has reviewed the Joint Motion for Teleconference to Resolve Discovery Disputes (D.I. 193 ). A discovery dispute teleconference is scheduled for December 8, 2023 at 1:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than December 5, 2023, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than December 6, 2023, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Jennifer L. Hall on 12/4/2023. (ceg) (Entered: 12/04/2023) (0) |
| Nov 30, 2023 | 194 | STIPULATION and [Proposed] Order Extending Expert Report Deadlines by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Haynes, Christine) Modified on 11/30/2023 (ceg). (Entered: 11/30/2023) (3) |
| Nov 29, 2023 | 193 | [SEALED] Joint MOTION for Teleconference to Resolve Discovery Disputes - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. Motions referred to Jennifer L. Hall. (Cottrell, Frederick) Modified on 11/30/2023 (ceg). (Entered: 11/29/2023) (0) |
| Nov 28, 2023 | 191 | STIPULATION and [Proposed] Order Extending Opening Expert Reports Deadline to November 30, 2023 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Haynes, Christine) Modified on 11/28/2023 (ceg). (Entered: 11/28/2023) (3) |
| Nov 28, 2023 | 192 | NOTICE OF SERVICE of Second Supplemental Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 11/28/2023) (2) |
| Nov 21, 2023 | 189 | NOTICE to Take Deposition of Daniel Snider on November 29, 2023 filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 11/21/2023) (2) |
| Nov 21, 2023 | 190 | STIPULATION and [Proposed] Order for opening expert reports shall be extended to Tuesday, November 28, 2023, and the deadline for responsive expert reports shall be extended to December 22, 2023. by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 11/21/2023) (3) |
| Nov 17, 2023 | 185 | Joint STIPULATION and [Proposed] Order of Dismissal of the '680, '313, '679 and '427 Patents by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 11/17/2023) (6) |
| Nov 17, 2023 | 186 | SO ORDERED, re 185 Joint Stipulation of Dismissal of the '680, '313, '679 and '427 Patents, filed by Viatris Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 11/17/2023. (kmd) (Entered: 11/17/2023) (6) |
| Nov 17, 2023 | 187 | NOTICE OF SERVICE of Plaintiffs' First Amended Validity Contentions filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 11/17/2023) (2) |
| Nov 17, 2023 | 188 | NOTICE OF SERVICE of Defendants First Amended Non-Infringement Contentions filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 11/17/2023) (2) |
| Nov 13, 2023 | 182 | Letter to The Honorable Jennifer L. Hall from Andrew C. Mayo regarding Plaintiff's response to Defendants' November 10, 2023 motion for discovery hearing - re 179 MOTION for Teleconference to Resolve Discovery Dispute . (Mayo, Andrew) (Entered: 11/13/2023) (2) |
| Nov 13, 2023 | 183 | ORAL ORDER: Having reviewed the Motion for Teleconference to Resolve Discovery Dispute (D.I. 179 ) and Plaintiffs' Letter (D.I. 182 ), IT IS HEREBY ORDERED that the Motion (D.I. 179 ) is DENIED WITHOUT PREJUDICE to renew after the parties meet & confer. Ordered by Judge Jennifer L. Hall on 11/13/2023. (ceg) (Entered: 11/13/2023) (0) |
| Nov 13, 2023 | 184 | MOTION for Pro Hac Vice Appearance of Attorney Bryan D. Beel - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. Motions referred to Jennifer L. Hall.(Haynes, Christine) (Entered: 11/13/2023) (3) |
| Nov 10, 2023 | 179 | MOTION for Teleconference to Resolve Discovery Dispute - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Text of Proposed Order)Motions referred to Jennifer L. Hall.(Cottrell, Frederick) (Entered: 11/10/2023) (0) |
| Nov 10, 2023 | 180 | NOTICE OF SERVICE of Plaintiffs' Supplemental Infringement Contentions filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 11/10/2023) (2) |
| Nov 10, 2023 | 181 | NOTICE OF SERVICE of First Amended Invalidity Contentions filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 11/10/2023) (2) |
| Nov 8, 2023 | 178 | STIPULATION and Proposed Order to Extend Deadlines - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Cottrell, Frederick) Modified on 11/13/2023 (ceg). (Entered: 11/08/2023) (2) |
| Nov 1, 2023 | 176 | MOTION for Pro Hac Vice Appearance of Attorney Eric J. Fues - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. Motions referred to Jennifer L. Hall.(Mayo, Andrew) (Entered: 11/01/2023) (3) |
| Nov 1, 2023 | 177 | STIPULATION TO EXTEND TIME for the parties to serve any final amendment of or supplement to the Infringement Contentions, Invalidity Contentions, Preliminary Disclosure of Asserted Claims, and Preliminary Disclosure of Asserted Prior Art to November 8, 2023 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 11/01/2023) (2) |
| Oct 31, 2023 | 174 | NOTICE to Take Deposition of Mary Hobart on November 7, 2023 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 10/31/2023) (2) |
| Oct 31, 2023 | 175 | NOTICE to Take Deposition of Tom Gibbs on November 1, 2023 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 10/31/2023) (2) |
| Oct 16, 2023 | 172 | NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Second Set of Interrogatories (Nos. 7-15) filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 10/16/2023) (2) |
| Oct 16, 2023 | 173 | NOTICE OF SERVICE of 1) Defendants Mylan Laboratories Limited, Viatris Inc., and Mylan Pharmaceuticals Inc. First Supplemental Responses to First Set of Interrogatories (Nos. 1-11) of Plaintiffs; 2) Responses to Plaintiffs Second Set of Requests for Production of Documents and Things (Nos. 76-93); 3) 30(b)(6) Objections and Responses (Nos. 1-41); and 4) Supplemental Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 10/16/2023) (2) |
| Oct 10, 2023 | 171 | RESPONSE TO OBJECTIONS by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. re 152 Objections, . (Balick, Steven) (Entered: 10/10/2023) (15) |
| Oct 9, 2023 | 170 | NOTICE OF SERVICE of Plaintiffs' Responses to Defendants' Notice of 30(b)(6) Deposition filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 10/09/2023) (2) |
| Oct 6, 2023 | 169 | Official Transcript of Markman Hearing held on 8/16/23 before Judge Jennifer Hall. Court Reporter Deanna Warner, Email: deanna_warner@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 10/27/2023. Redacted Transcript Deadline set for 11/6/2023. Release of Transcript Restriction set for 1/4/2024. (Warner, Deanna) (Entered: 10/06/2023) (98) |
| Oct 2, 2023 | 166 | MOTION for Pro Hac Vice Appearance of Attorney Christopher D. Jones - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. Motions referred to Jennifer L. Hall.(Haynes, Christine) (Entered: 10/02/2023) (3) |
| Oct 2, 2023 | 167 | NOTICE OF SERVICE of Plaintiffs' Responses to Defendants' Second Set of Requests for Production of Documents and Things (Nos. 101-112) filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 10/02/2023) (2) |
| Oct 2, 2023 | 168 | NOTICE OF SERVICE of Subpoena Ad Testificandum on Josiah Brown filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit A)(Haynes, Christine) (Entered: 10/02/2023) (0) |
| Sep 29, 2023 | 155 | NOTICE to Take Deposition of Ajay Gautam on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 29, 2023 | 156 | NOTICE to Take Deposition of Dave Mitchell on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 29, 2023 | 157 | NOTICE to Take Deposition of Wayne Talton on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 29, 2023 | 158 | NOTICE to Take Deposition of Venkat Ramana R. Koluri on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 29, 2023 | 159 | NOTICE to Take Deposition of Vishwas Laxmanrao Sherkar on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 29, 2023 | 160 | NOTICE to Take Deposition of Srinivas Meda on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 29, 2023 | 161 | NOTICE to Take Deposition of Sureshbabu Jayachandra on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 29, 2023 | 162 | NOTICE to Take Deposition of Shrikant Dhage on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 29, 2023 | 163 | NOTICE to Take Deposition of Ruchira Sarbajna on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 29, 2023 | 164 | NOTICE to Take Deposition of Nitin Bhattad on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 29, 2023 | 165 | NOTICE to Take Deposition of Katie Reed on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/29/2023) (2) |
| Sep 28, 2023 | 154 | Letter to The Honorable Colm F. Connolly from Christine D. Haynes regarding enclosing courtesy copies of documents associated with Defendants' Objections to the Magistrate Judge's Report and Recommendation. (Haynes, Christine) (Entered: 09/28/2023) (2) |
| Sep 26, 2023 | 152 | OBJECTIONS by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. to 144 REPORT AND RECOMMENDATIONS re 121 MOTION for Claim Construction filed by Viatris Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., 120 MOTION for Claim Construction filed by Otsuka Pharmaceutical Co., . (Attachments: # 1 Certificate of Compliance, # 2 Certificate of Compliance With Standing Order for Objections)(Cottrell, Frederick) (Entered: 09/26/2023) (0) |
| Sep 26, 2023 | 153 | NOTICE OF SERVICE of Corrected Responses to First Set of Requests for Production of Documents and Things (Nos. 1-75) filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 09/26/2023) (2) |
| Sep 15, 2023 | 145 | NOTICE OF SERVICE of Notice of Deposition of Defendants Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) and Plaintiffs' Second Set of Requests for Production of Documents and Things (Nos. 76-93) to Defendants Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc. filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 09/15/2023) (2) |
| Sep 15, 2023 | 146 | NOTICE OF SERVICE of Second Set of Interrogatories to Plaintiffs (Nos. 7-15) filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 09/15/2023) (2) |
| Sep 15, 2023 | 147 | NOTICE to Take Deposition of Satoshi Aoki on October 5, 2023 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc..(Haynes, Christine) (Entered: 09/15/2023) (2) |
| Sep 15, 2023 | 148 | NOTICE to Take Deposition of Takuji Bando on October 3, 2023 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc..(Haynes, Christine) (Entered: 09/15/2023) (2) |
| Sep 15, 2023 | 149 | NOTICE to Take Deposition of Josiah Brown on September 28, 2023 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc..(Haynes, Christine) (Entered: 09/15/2023) (2) |
| Sep 15, 2023 | 150 | NOTICE to Take Deposition of Robert McQuade on October 12, 2023 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc..(Haynes, Christine) (Entered: 09/15/2023) (2) |
| Sep 15, 2023 | 151 | NOTICE to Take Deposition of Arash Raoufinia on October 10, 2023 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc..(Haynes, Christine) (Entered: 09/15/2023) (2) |
| Sep 12, 2023 | 144 | REPORT AND RECOMMENDATION re Claim Construction Disputes (D.I. 120 , D.I. 121 ). Please note that when filing Objections pursuant to Federal Rule of Civil Procedure 72(b)(2), briefing consists solely of the Objections (no longer than ten (10) pages) and the Response to the Objections (no longer than ten (10) pages). No further briefing shall be permitted with respect to objections without leave of the Court. Objections to R&R due by 9/26/2023. Signed by Judge Jennifer L. Hall on 9/12/2023. (ceg) (Entered: 09/12/2023) (16) |
| Sep 6, 2023 | 143 | NOTICE OF SERVICE of Defendants Mylan Laboratories Limited, Viatris Inc., and Mylan Pharmaceuticals Inc. Notice of Rule 30(b)(6) Notice of Deposition of Plaintiffs Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc..(Haynes, Christine) (Entered: 09/06/2023) (2) |
| Sep 1, 2023 | 142 | NOTICE OF SERVICE of Second Set of Requests for Production of Documents (Nos. 101-112) filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 09/01/2023) (2) |
| Aug 15, 2023 | 140 | Unopposed MOTION For Exemption of Persons From The District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Text of Proposed Order)Motions referred to Jennifer L. Hall.(Haynes, Christine) (Entered: 08/15/2023) (0) |
| Aug 15, 2023 | 141 | ORDER granting 140 Unopposed Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. Signed by Judge Jennifer L. Hall on 8/15/2023. (ceg) (Entered: 08/15/2023) (2) |
| Aug 9, 2023 | 139 | NOTICE OF SERVICE of (1) Defendants Responses to First Set of Interrogatories (Nos. 1-11); (2) Responses to First Set of Requests for Admission (Nos. 1-5) and (3) Responses to First Set of Requests for Production of Documents and Things (Nos. 1-75) of Plaintiffs filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 08/09/2023) (2) |
| Aug 3, 2023 | 138 | NOTICE OF SERVICE of Amended Discovery Disclosures Pursuant to Paragraph 3 of the District of Delaware's Default Standard filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 08/03/2023) (2) |
| Jul 21, 2023 | 135 | ORAL ORDER: The Markman hearing is now scheduled for August 16, 2023 at 10:30 AM before Judge Hall in courtroom TBD. Each side shall be allocated 90 minutes for its presentation (i.e., the total allocation of time for the hearing will be 3 hours). Any slide presentations or demonstratives that the parties wish to use during the hearing shall be emailed to Cailah_Garfinkel@ded.uscourts.gov no later than 24 hours prior to the hearing. Ordered by Judge Jennifer L. Hall on 7/21/2023. (ceg) (Entered: 07/21/2023) (0) |
| Jul 21, 2023 | 136 | Letter to The Honorable Jennifer L. Hall from Andrew C. Mayo regarding amended joint claim chart. (Mayo, Andrew) (Entered: 07/21/2023) (1) |
| Jul 21, 2023 | 137 | AMENDED Joint Claim Construction Chart by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) Modified on 7/24/2023 (ceg). (Entered: 07/21/2023) (12) |
| Jul 18, 2023 | 133 | JOINT CLAIM CONSTRUCTION BRIEF filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. (Mayo, Andrew) (Entered: 07/18/2023) (30) |
| Jul 18, 2023 | 134 | Joint APPENDIX re 133 Joint Claim Construction Brief by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-16, # 2 Exhibit 17-28)(Mayo, Andrew) (Entered: 07/18/2023) (0) |
| Jul 14, 2023 | 132 | STIPULATION and Proposed Order to Extend deadline to file the Joint Claim Construction Brief and the Amended Joint Claim Construction Chart by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Haynes, Christine) Modified on 7/14/2023 (ceg). (Entered: 07/14/2023) (2) |
| Jul 12, 2023 | 131 | ORDER REFERRING CASE to Magistrate Judge Jennifer L. Hall to conduct all proceedings and hear and determine all motions. Signed by Judge Colm F. Connolly on 7/12/2023. Motions referred to Judge Jennifer L. Hall.(nmf) (Entered: 07/12/2023) (1) |
| Jul 11, 2023 | 130 | NOTICE OF SERVICE of Plaintiffs' Second Amended Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 07/11/2023) (2) |
| Jul 10, 2023 | 129 | NOTICE OF SERVICE of (i) Plaintiffs' First Set of Interrogatories (Nos. 1-11) to Defendants Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc.; (ii) Plaintiffs' First Set of Requests for Admission (Nos. 1-5) to Defendants Mylan Laboratories Limited, Viatris, Inc. and Mylan Pharmaceuticals Inc.; and (iii) Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-75) to Defendants Mylan Laboratories Limited, Viatris, Inc. and Mylan Pharmaceuticals Inc. filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 07/10/2023) (2) |
| Jul 3, 2023 | 128 | NOTICE OF SERVICE of Plaintiffs' Reply Claim Construction Brief filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 07/03/2023) (2) |
| Jun 27, 2023 | 126 | NOTICE OF SERVICE of Defendants' Answering Claim Construction Brief filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 06/27/2023) (2) |
| Jun 27, 2023 | 127 | MOTION for Pro Hac Vice Appearance of Attorney David L. Anstaett - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 06/27/2023) (3) |
| Jun 23, 2023 | 125 | NOTICE OF SERVICE of (i) Plaintiffs' Responses to Defendants' Requests for Production of Documents (Nos. 1-100); (ii) Plaintiffs' Objections and Responses to Defendants' First Set of Interrogatories (Nos. 16); and (iii) Plaintiffs' Amended Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 06/23/2023) (2) |
| Jun 21, 2023 | 124 | NOTICE OF SERVICE of Plaintiffs' Amended Disclosure Pursuant to Paragraph 9 filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 06/21/2023) (2) |
| Jun 12, 2023 | 123 | NOTICE OF SERVICE of Plaintiffs' Opening Claim Construction Brief filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 06/12/2023) (2) |
| Jun 9, 2023 | 122 | NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions and Plaintiffs' Initial Disclosures Pursuant to Paragraph 9(d) of the Scheduling Order filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 06/09/2023) (2) |
| Jun 5, 2023 | 118 | Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Joint Response to the Court's May 22, 2023 Oral Order Concerning Possible Referral to a Magistrate Judge. (Balick, Steven) (Entered: 06/05/2023) (1) |
| Jun 5, 2023 | 119 | CLAIM Construction Chart by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-10)(Balick, Steven) (Entered: 06/05/2023) (Main Document) (10) |
| Jun 5, 2023 | 120 | MOTION for Claim Construction - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 06/05/2023) (2) |
| Jun 5, 2023 | 121 | MOTION for Claim Construction - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 06/05/2023) (2) |
| Jun 5, 2023 | 119 | CLAIM Construction Chart by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-10)(Balick, Steven) (Entered: 06/05/2023) (Exhibit 1-10) (30) |
| May 24, 2023 | 117 | NOTICE OF SERVICE of Plaintiffs' Initial Validity Contentions filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 05/24/2023) (2) |
| May 23, 2023 | 116 | NOTICE OF SERVICE of Plaintiffs' Disclosure Regarding Claim Terms Needing Construction and Proposed Constructions, filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 05/23/2023) (2) |
| May 22, 2023 | 114 | MOTION for Pro Hac Vice Appearance of Attorney Alexandra ("A. Sasha") Hoyt - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 05/22/2023) (3) |
| May 22, 2023 | 115 | NOTICE OF SERVICE of Defendants' Proposed Constructions filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 05/22/2023) (2) |
| May 16, 2023 | 113 | NOTICE OF SERVICE of Defendants' 1) First Set of Interrogatories to Plaintiffs (Nos. 1-6) and 2) First Set of Requests for Production of Documents (Nos. 1-100) filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 05/16/2023) (2) |
| Apr 24, 2023 | 112 | NOTICE OF SERVICE of 1) Defendants Non-Infringement Contentions and 2) Defendants Invalidity Contentions filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 04/24/2023) (2) |
| Mar 27, 2023 | 111 | Official Transcript of Telephonic Scheduling Conference held on March 8, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/17/2023. Redacted Transcript Deadline set for 4/27/2023. Release of Transcript Restriction set for 6/26/2023. (nmf) (Entered: 03/27/2023) (16) |
| Mar 24, 2023 | 106 | NOTICE OF SERVICE of Plaintiffs' Preliminary Disclosure of Asserted Claims filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 03/24/2023) (3) |
| Mar 24, 2023 | 107 | ANSWER to 93 Answer to Complaint, Counterclaim (Plaintiffs' Answer and Defenses to Defendant Mylan Pharmaceuticals Inc.'s Counterclaims (C.A. No. 22-464-CFC)) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 03/24/2023) (24) |
| Mar 24, 2023 | 108 | ANSWER to 94 Answer to Complaint, Counterclaim (Plaintiffs' Answer and Defenses to Defendant Mylan Pharmaceuticals Inc.'s Counterclaims (C.A. No. 22-1125-CFC)) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 03/24/2023) (9) |
| Mar 24, 2023 | 109 | ANSWER to 95 Answer to Complaint, Counterclaim (Plaintiffs' Answer and Defenses to Defendant Mylan Pharmaceuticals Inc.'s Counterclaims (C.A. No. 22-1226-CFC)) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 03/24/2023) (9) |
| Mar 24, 2023 | 110 | ANSWER to 96 Answer to Complaint, Counterclaim (Plaintiffs' Answer and Defenses to Defendant Mylan Pharmaceuticals Inc.'s Counterclaims (C.A. No. 22-1367-CFC)) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Balick, Steven) (Entered: 03/24/2023) (9) |
| Mar 22, 2023 | 104 | NOTICE OF SERVICE of Defendants' 1) Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); and 2) Discovery Disclosures Pursuant to Paragraph 3 of the District of Delaware's Default Standard filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 03/22/2023) (2) |
| Mar 22, 2023 | 105 | NOTICE OF SERVICE of Plaintiffs' Initial Disclosure Statement Pursuant to Fed. R. Civ. P. 26(a)(1) and Plaintiffs' Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 03/22/2023) (2) |
| Mar 20, 2023 | 103 | STIPULATED PROTECTIVE ORDER. Signed by Judge Colm F. Connolly on 3/20/2023. (kmd) (Entered: 03/20/2023) (30) |
| Mar 17, 2023 | 101 | SCHEDULING ORDER: Joinder of Parties due by 5/15/2023. Amended Pleadings due by 5/15/2023. Fact Discovery completed by 10/16/2023. Expert Discovery due by 2/2/2024. Joint Claim Construction Brief due by 7/14/2023. A Markman Hearing is set for 8/1/2023 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 2/13/2024. A Final Pretrial Conference is set for 3/5/2024 at 03:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 4/1/2024 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 3/17/2023. (nmf) (Entered: 03/17/2023) (19) |
| Mar 17, 2023 | 102 | PROPOSED ORDER (Stipulated Protective Order), by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 03/17/2023) (30) |
| Mar 15, 2023 | 99 | Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding Proposed Scheduling Order. (Balick, Steven) (Entered: 03/15/2023) (1) |
| Mar 15, 2023 | 100 | PROPOSED ORDER (Scheduling Order) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 03/15/2023) (19) |
| Mar 7, 2023 | 97 | Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Jointly Proposed Scheduling Order. (Balick, Steven) (Entered: 03/07/2023) (1) |
| Mar 7, 2023 | 98 | PROPOSED ORDER (Proposed Scheduling Order) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 03/07/2023) (20) |
| Mar 3, 2023 | 93 | ANSWER to 1 Complaint, pertaining to C.A. No. 22-464-CFC, COUNTERCLAIM against All Plaintiffs by Viatris Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc..(Cottrell, Frederick) (Entered: 03/03/2023) (30) |
| Mar 3, 2023 | 94 | ANSWER to Complaint pertaining to C.A. No. 22-1125-CFC, COUNTERCLAIM against All Plaintiffs by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Cottrell, Frederick) (Entered: 03/03/2023) (30) |
| Mar 3, 2023 | 95 | ANSWER to Complaint pertaining to C.A. No. 22-1226-CFC, COUNTERCLAIM against All Plaintiffs by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Cottrell, Frederick) (Entered: 03/03/2023) (30) |
| Mar 3, 2023 | 96 | ANSWER to Complaint pertaining to C.A. No. 22-1367-CFC, COUNTERCLAIM against All Plaintiffs by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Cottrell, Frederick) (Entered: 03/03/2023) (30) |
| Feb 21, 2023 | 90 | SO ORDERED, re (89 in 1:22-cv-00464-CFC, 45 in 1:22-cv-01226-CFC, 54 in 1:22-cv-01125-CFC, 46 in 1:22-cv-01367-CFC) STIPULATION TO EXTEND TIME to submit a Proposed Protective Order to through and including March 10, 2023, filed by Viatris Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 2/21/2023. Associated Cases: 1:22-cv-00464-CFC, 1:22-cv-01125-CFC, 1:22-cv-01226-CFC, 1:22-cv-01367-CFC(kmd) (Entered: 02/21/2023) (2) |
| Feb 21, 2023 | 91 | STIPULATION and Proposed Order Regarding Withdrawal of Venue Motions, Consolidation of Actions and Submission of Case Schedule re (32 in 1:22-cv-01125-CFC, 67 in 1:22-cv-00464-CFC, 23 in 1:22-cv-01226-CFC, 24 in 1:22-cv-01367-CFC) Order Staying Case, (51 in 1:22-cv-01125-CFC, 42 in 1:22-cv-01226-CFC, 86 in 1:22-cv-00464-CFC, 43 in 1:22-cv-01367-CFC) Letter,, (42 in 1:22-cv-01367-CFC, 85 in 1:22-cv-00464-CFC, 50 in 1:22-cv-01125-CFC) Notice (Other),,, (41 in 1:22-cv-01226-CFC) Notice (Other),, by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Pharmaceuticals Inc.. (Haynes, Christine) (Entered: 02/21/2023) (5) |
| Feb 21, 2023 | 92 | SO ORDERED re (47 in 1:22-cv-01226-CFC, 56 in 1:22-cv-01125-CFC, 91 in 1:22-cv-00464-CFC, 48 in 1:22-cv-01367-CFC) STIPULATION AND ORDER REGARDING WITHDRAWAL OF VENUE MOTIONS, CONSOLIDATION OF ACTIONS AND SUBMISSION OF CASE SCHEDULE. CIVIL ACTION NO. 22-464-CFC SHALL BE THE LEAD CASE AND ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 22-464-CFC ONLY. ORDER LIFTING STAY. Order Setting Telephonic Scheduling Conference:( A Scheduling Conference is set for 3/8/2023 at 03:30 PM before Judge Colm F. Connolly. If the parties have no disputes regarding the scheduling order, the Court will not require the parties to appear at a conference. Signed by Judge Colm F. Connolly on 2/21/2023. Associated Cases: 1:22-cv-00464-CFC, 1:22-cv-01125-CFC, 1:22-cv-01226-CFC, 1:22-cv-01367-CFC(nmf) (Entered: 02/21/2023) (5) |
| Feb 17, 2023 | 89 | STIPULATION TO EXTEND TIME to submit a Proposed Protective Order to through and including March 10, 2023 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Pharmaceuticals Inc.. (Haynes, Christine) (Entered: 02/17/2023) (2) |
| Feb 6, 2023 | 88 | SO ORDERED, re (52 in 1:22-cv-01125-CFC, 87 in 1:22-cv-00464-CFC, 43 in 1:22-cv-01226-CFC, 44 in 1:22-cv-01367-CFC) STIPULATION TO EXTEND TIME for parties to submit a proposed protective order to February 17, 2023, filed by Viatris Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 2/6/2023. Associated Cases: 1:22-cv-00464-CFC, 1:22-cv-01125-CFC, 1:22-cv-01226-CFC, 1:22-cv-01367-CFC(kmd) (Entered: 02/06/2023) (2) |
| Feb 3, 2023 | 87 | STIPULATION TO EXTEND TIME for parties to submit a proposed protective order to February 17, 2023 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Pharmaceuticals Inc.. (Haynes, Christine) (Entered: 02/03/2023) (2) |
| Feb 1, 2023 | 85 | NOTICE of withdraw Defendants MPI and Viatris motions to dismiss for improper venue, failure to state a claim, and lack of subject matter jurisdiction (Case No. 22-464, D.I. 17; Case No. 22-1125, D.I. 12; Case No. 22-1226, D.I. 12; Case No. 22-1367, D.I. 13). Defendant MLL withdraws its motion to transfer (Case No. 22-464, D.I. 49) by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Pharmaceuticals Inc. re (13 in 1:22-cv-01367-CFC) MOTION to Dismiss for Failure to State a Claim , (49 in 1:22-cv-00464-CFC) MOTION to Transfer or Dismiss , (12 in 1:22-cv-01125-CFC) MOTION to Dismiss for Improper Venue , (17 in 1:22-cv-00464-CFC) MOTION to Dismiss for Improper Venue (Cottrell, Frederick) (Entered: 02/01/2023) (2) |
| Feb 1, 2023 | 86 | Letter to The Honorable Colm F. Connolly from Frederick L. Cottrell, III regarding Notice of Withdrawal withdrawing MPI and Viatris pending motions to dismiss for improper venue, failure to state a claim, and lack of subject matter jurisdiction - re (13 in 1:22-cv-01367-CFC) MOTION to Dismiss for Failure to State a Claim , (42 in 1:22-cv-01367-CFC, 85 in 1:22-cv-00464-CFC, 50 in 1:22-cv-01125-CFC) Notice (Other),,, (41 in 1:22-cv-01226-CFC) Notice (Other),, (12 in 1:22-cv-01226-CFC) MOTION to Dismiss for Failure to State a Claim , (12 in 1:22-cv-01125-CFC) MOTION to Dismiss for Improper Venue , (17 in 1:22-cv-00464-CFC) MOTION to Dismiss for Improper Venue . (Cottrell, Frederick) (Entered: 02/01/2023) (2) |
| Jan 27, 2023 | 84 | SO ORDERED, re (40 in 1:22-cv-01367-CFC, 39 in 1:22-cv-01226-CFC, 48 in 1:22-cv-01125-CFC, 83 in 1:22-cv-00464-CFC) STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to February 3, 2023, filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 1/27/2023. Associated Cases: 1:22-cv-00464-CFC, 1:22-cv-01125-CFC, 1:22-cv-01226-CFC, 1:22-cv-01367-CFC(kmd) (Entered: 01/27/2023) (2) |
| Jan 26, 2023 | 83 | STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to February 3, 2023 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Haynes, Christine) (Entered: 01/26/2023) (2) |
| Jan 20, 2023 | 82 | SO ORDERED, re (46 in 1:22-cv-01125-CFC, 81 in 1:22-cv-00464-CFC, 38 in 1:22-cv-01367-CFC, 37 in 1:22-cv-01226-CFC) STIPULATION TO EXTEND TIME for parties to submit a proposed protective order to January 27, 2023, filed by Viatris Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 1/20/2023. Associated Cases: 1:22-cv-00464-CFC, 1:22-cv-01125-CFC, 1:22-cv-01226-CFC, 1:22-cv-01367-CFC(kmd) (Entered: 01/20/2023) (2) |
| Jan 19, 2023 | 81 | STIPULATION TO EXTEND TIME for parties to submit a proposed protective order to January 27, 2023 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Pharmaceuticals Inc.. (Haynes, Christine) (Entered: 01/19/2023) (2) |
| Jan 13, 2023 | 79 | STIPULATION Seeking to Extend the Deadline by which a Proposed Protective Order is Due, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 80 | SO ORDERED, re (79 in 1:22-cv-00464-CFC, 35 in 1:22-cv-01226-CFC, 44 in 1:22-cv-01125-CFC, 36 in 1:22-cv-01367-CFC) Stipulation Seeking to Extend the Deadline by which a Proposed Protective Order is Due, filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. The deadline by which the parties must submit a proposed protective order in each of the four actions is extended through and including January 20, 2023. Signed by Judge Colm F. Connolly on 1/13/2023. Associated Cases: 1:22-cv-00464-CFC, 1:22-cv-01125-CFC, 1:22-cv-01226-CFC, 1:22-cv-01367-CFC(kmd) (Entered: 01/13/2023) (2) |
| Jan 6, 2023 | 68 | NOTICE OF SERVICE of Plaintiffs' First Set of Interrogatories (Nos. 1-24) to Defendants Viatris, MLL and MPI and Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-73) to Defendants Viatris, MLL and MPI filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 69 | NOTICE to Take Deposition of Amy L. Martin on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 70 | NOTICE to Take Deposition of Jude Christopher Gorski on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 71 | NOTICE to Take Deposition of Keith Meckstroth on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 72 | NOTICE to Take Deposition of Michael Plastina on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 73 | NOTICE to Take Deposition of Satyanarayana Jujjavarapu on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 74 | NOTICE OF SERVICE of First Set of Interrogatories filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc..(Haynes, Christine) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 75 | NOTICE to Take Deposition of Wayne Talton on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 76 | NOTICE OF SERVICE of Notice of Deposition of Defendant Mylan Laboratories Limited Pursuant to Rule 30(b)(6), Notice of Deposition of Defendant Mylan Pharmaceuticals Inc. Pursuant to Rule 30(b)(6), and Notice of Deposition of Defendant Viatris Inc. Pursuant to Rule 30(b)(6) filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 77 | NOTICE to Take Deposition of Jerry Toppins on a time and place to be agreed upon by the parties - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 78 | NOTICE OF SERVICE of Plaintiffs' First Set of Requests for Admission (Nos. 1-5) to Defendants Viatris, MLL and MPI filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..(Mayo, Andrew) (Entered: 01/06/2023) (2) |
| Dec 16, 2022 | 67 | ORDER REGARDING DISCOVERY AND STAY OF ALL OTHER PROCEEDINGS. (SEE ORDER FOR FURTHER DETAILS.) Signed by Judge Colm F. Connolly on 12/16/2022. Associated Cases: 1:22-cv-00464-CFC, 1:22-cv-01125-CFC, 1:22-cv-01226-CFC, 1:22-cv-01367-CFC(nmf) (Entered: 12/16/2022) (4) |
| Dec 15, 2022 | 66 | Letter to The Honorable Colm F. Connolly from Andrew C. Mayo regarding proposed order for discovery and stay of other proceedings. (Attachments: # 1 Text of Proposed Order)(Mayo, Andrew) (Entered: 12/15/2022) (Main Document) (2) |
| Dec 15, 2022 | 66 | Letter to The Honorable Colm F. Connolly from Andrew C. Mayo regarding proposed order for discovery and stay of other proceedings. (Attachments: # 1 Text of Proposed Order)(Mayo, Andrew) (Entered: 12/15/2022) (Text of Proposed Order) (4) |
| Dec 9, 2022 | 65 | Joint STIPULATION TO EXTEND TIME to Submit a Form of Proposed Order to December 15, 2022 - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 12/09/2022) (2) |
| Dec 7, 2022 | 64 | Official Transcript of Oral Argument held on December 2, 2022 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 12/28/2022. Redacted Transcript Deadline set for 1/9/2023. Release of Transcript Restriction set for 3/7/2023. (nmf) (Entered: 12/07/2022) (93) |
| Nov 30, 2022 | 63 | MOTION for Pro Hac Vice Appearance of Attorney Paul W. Browning and Jennifer H. Roscetti - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 11/30/2022) (4) |
| Nov 29, 2022 | 62 | NOTICE of Appearance by Jason James Rawnsley on behalf of Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Rawnsley, Jason) (Entered: 11/29/2022) (1) |
| Nov 1, 2022 | 59 | REQUEST for Oral Argument by Mylan Laboratories Limited re 49 MOTION to Transfer or Dismiss . (Cottrell, Frederick) (Entered: 11/01/2022) (2) |
| Nov 1, 2022 | 60 | REDACTED VERSION of 56 Reply Brief by Mylan Laboratories Limited. (Cottrell, Frederick) (Entered: 11/01/2022) (17) |
| Nov 1, 2022 | 61 | REQUEST for Oral Argument by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. re 49 MOTION to Transfer or Dismiss . (Balick, Steven) (Entered: 11/01/2022) (2) |
| Oct 27, 2022 | 58 | REDACTED VERSION of 54 Answering Brief in Opposition by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 10/27/2022) (29) |
| Oct 26, 2022 | 57 | SO ORDERED, re 55 STIPULATION TO EXTEND TIME to file redactions to October 27, 2022, filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. Signed by Judge Colm F. Connolly on 10/26/2022. (kmd) (Entered: 10/26/2022) (2) |
| Oct 25, 2022 | 55 | STIPULATION TO EXTEND TIME to file redactions to October 27, 2022 - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 10/25/2022) (2) |
| Oct 25, 2022 | 56 | [SEALED] REPLY BRIEF re 49 MOTION to Transfer or Dismiss filed by Mylan Laboratories Limited. (Cottrell, Frederick) (Entered: 10/25/2022) (0) |
| Oct 18, 2022 | 54 | [SEALED] ANSWERING BRIEF in Opposition re 49 MOTION to Transfer or Dismiss filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..Reply Brief due date per Local Rules is 10/25/2022. (Balick, Steven) (Entered: 10/18/2022) (0) |
| Oct 12, 2022 | 53 | NOTICE of Absence of Consent to Proceed Before A United States Magistrate Judge, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. (Balick, Steven) (Entered: 10/12/2022) (1) |
| Oct 4, 2022 | 49 | MOTION to Transfer or Dismiss - filed by Mylan Laboratories Limited. (Attachments: # 1 Text of Proposed Order)(Haynes, Christine) (Entered: 10/04/2022) (Main Document) (3) |
| Oct 4, 2022 | 50 | OPENING BRIEF in Support re 49 MOTION to Transfer or Dismiss filed by Mylan Laboratories Limited.Answering Brief/Response due date per Local Rules is 10/18/2022. (Haynes, Christine) (Entered: 10/04/2022) (25) |
| Oct 4, 2022 | 51 | DECLARATION re 49 MOTION to Transfer or Dismiss by Mylan Laboratories Limited. (Attachments: # 1 Exhibit A)(Haynes, Christine) (Entered: 10/04/2022) (Main Document) (1) |
| Oct 4, 2022 | 52 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Viatris Inc., Other Affiliate Mylan Inc. for Mylan Laboratories Limited filed by Mylan Laboratories Limited. (Haynes, Christine) (Entered: 10/04/2022) (2) |
| Oct 4, 2022 | 51 | DECLARATION re 49 MOTION to Transfer or Dismiss by Mylan Laboratories Limited. (Attachments: # 1 Exhibit A)(Haynes, Christine) (Entered: 10/04/2022) (Exhibit A) (4) |
| Oct 4, 2022 | 49 | MOTION to Transfer or Dismiss - filed by Mylan Laboratories Limited. (Attachments: # 1 Text of Proposed Order)(Haynes, Christine) (Entered: 10/04/2022) (Text of Proposed Order) (1) |
| Sep 28, 2022 | 48 | ORAL ORDER: It is HEREBY ORDERED that on or before October 12, 2022, the parties shall, after meeting and conferring, complete and file the "Notice of Consent or Absence of Consent to Proceed Before A United States Magistrate Judge" that has been docketed with this Order. Ordered by Judge Colm F. Connolly on 9/28/2022. (nmf) (Entered: 09/28/2022) (1) |
| Sep 6, 2022 | 47 | STIPULATION and [Proposed] Order for Defendant to Move, Answer or Otherwise Respond to the Complaint is October 4, 2022 by Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) (Entered: 09/06/2022) (2) |
| Aug 5, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Emily J. Greb for Mylan Laboratories Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Aug 4, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [43] Stipulation for Defendants Viatris Inc. and Mylan Pharmaceuticals Inc. to file redacted versions of their Reply Brief in further support of their Motion to Dismiss, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Ordered by Judge Colm F. Connolly on 8/4/2022. (kmd) |
| Aug 4, 2022 | 44 | Redacted Document (18) Docket Text: REDACTED VERSION of [37] Reply Brief by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Cottrell, Frederick) |
| Aug 4, 2022 | 45 | Main Document (8) Docket Text: REDACTED VERSION of [38] Declaration [Keith Meckstroth] by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # (1) Exhibit A-G)(Cottrell, Frederick) |
| Aug 4, 2022 | 45 | Exhibit A-G (361) |
| Aug 4, 2022 | 46 | Main Document (2) Docket Text: REDACTED VERSION of [39] Declaration [Brandon M. White] by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # (1) Exhibit A-B)(Cottrell, Frederick) |
| Aug 4, 2022 | 46 | Exhibit A-B (141) |
| Aug 3, 2022 | 41 | Request for Oral Argument (2) Docket Text: REQUEST for Oral Argument by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. re [17] MOTION to Dismiss for Improper Venue . (Balick, Steven) |
| Aug 3, 2022 | 42 | Request for Oral Argument (2) Docket Text: REQUEST for Oral Argument by Mylan Pharmaceuticals Inc., Viatris Inc. re [17] MOTION to Dismiss for Improper Venue . (Cottrell, Frederick) |
| Aug 3, 2022 | 43 | Stipulation (2) Docket Text: STIPULATION and [Proposed] Order for Defendants Viatris Inc. and Mylan Pharmaceuticals Inc. to file redacted versions of their Reply Brief in further support of their Motion to Dismiss by Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) |
| Aug 2, 2022 | 40 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S: For Mylan Laboratories Limited waiver sent on 7/6/2022, answer due 9/6/2022. (Mayo, Andrew) |
| Jul 27, 2022 | 35 | Stipulation (2) Docket Text: STIPULATION Regarding Filing the Reply Brief and Related Papers in Support of the Motion to Dismiss Under Seal by Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) |
| Jul 27, 2022 | 36 | SO ORDERED (2) Docket Text: SO ORDERED, re [35] Stipulation Regarding Filing the Reply Brief and Related Papers in Support of the Motion to Dismiss Under Seal, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 7/27/2022. (kmd) |
| Jul 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [29] MOTION for Pro Hac Vice Appearance of Attorney James B. Monroe, Denise Main, Erin M. Sommers, Jeanette M. Roorda, and Melanie Magdun, filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. Ordered by Judge Colm F. Connolly on 7/19/2022. (kmd) |
| Jul 19, 2022 | 31 | SO ORDERED (2) Docket Text: SO ORDERED, re [30] STIPULATION TO EXTEND TIME for Plaintiffs to file a redacted version of the papers filed under seal at D.I. 26-28 to through and including July 19, 2022, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 7/19/2022. (kmd) |
| Jul 19, 2022 | 32 | Redacted Document (30) Docket Text: REDACTED VERSION of [26] Answering Brief in Opposition by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jul 19, 2022 | 33 | Main Document (20) Docket Text: REDACTED VERSION of [27] Declaration, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # (1) Exhibit 1-22, # (2) Exhibit 23 part 1, # (3) Exhibit 23 part 2, # (4) Exhibit 24-44, # (5) Exhibit 45, # (6) Exhibit 46-60)(Mayo, Andrew) |
| Jul 19, 2022 | 33 | Exhibit 1-22 (233) |
| Jul 19, 2022 | 33 | Exhibit 23 part 1 (84) |
| Jul 19, 2022 | 33 | Exhibit 23 part 2 (89) |
| Jul 19, 2022 | 33 | Exhibit 24-44 (67) |
| Jul 19, 2022 | 33 | Exhibit 45 (367) |
| Jul 19, 2022 | 33 | Exhibit 46-60 (237) |
| Jul 19, 2022 | 34 | Main Document (1) Docket Text: REDACTED VERSION of [28] Declaration by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # (1) Exhibit 61-74, # (2) Exhibit 75-84, # (3) Exhibit 85-93)(Mayo, Andrew) |
| Jul 19, 2022 | 34 | Exhibit 61-74 (169) |
| Jul 19, 2022 | 34 | Exhibit 75-84 (110) |
| Jul 19, 2022 | 34 | Exhibit 85-93 (90) |
| Jul 18, 2022 | 29 | Motion for Leave to Appear Pro Hac Vice (8) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney James B. Monroe, Denise Main, Erin M. Sommers, Jeanette M. Roorda, and Melanie Magdun - filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Jul 18, 2022 | 30 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Plaintiffs to file a redacted version of the papers filed under seal at D.I. 26-28 to through and including July 19, 2022 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) |
| Jul 8, 2022 | 25 | SO ORDERED (2) Docket Text: SO ORDERED, re [24] Stipulation Seeking to Extend the Deadlines for Briefing on the Pending Motion to Dismiss, filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. Reset Briefing Schedule: re [17] MOTION to Dismiss for Improper Venue. Answering Brief due 7/11/2022. Reply Brief due 7/27/2022. Signed by Judge Colm F. Connolly on 7/8/2022. (kmd) |
| Jul 7, 2022 | 24 | Stipulation (2) Docket Text: STIPULATION Seeking to Extend the Deadlines for Briefing on the Pending Motion to Dismiss, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Jun 29, 2022 | 23 | SO ORDERED (2) Docket Text: SO ORDERED, re [22] Stipulation Regarding Briefing Schedule, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Reset Briefing Schedule: re [17] MOTION to Dismiss for Improper Venue. Answering Brief due 7/7/2022., Reply Brief due 7/21/2022. Signed by Judge Colm F. Connolly on 6/29/2022. (kmd) |
| Jun 28, 2022 | 22 | Stipulation (2) Docket Text: STIPULATION Regarding Briefing Schedule by Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) |
| Jun 24, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Jonathan I Tietz for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Viatris Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Jun 22, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [21] MOTION for Pro Hac Vice Appearance of Attorney Jonathan Tietz of Perkins Coie LLP, filed by Viatris Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Ordered by Judge Colm F. Connolly on 6/22/2022. (kmd) |
| Jun 21, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Shannon M. Bloodworth for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Viatris Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Jun 21, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Brandon M. White for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Viatris Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Jun 21, 2022 | 21 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jonathan Tietz of Perkins Coie LLP - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) |
| Jun 17, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [14] MOTION for Pro Hac Vice Appearance of Attorney Brandon M. White, Shannon M. Bloodworth, Emily J. Greb and Maria A. Stubbings of Perkins Coie LLP, filed by Viatris Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Ordered by Judge Colm F. Connolly on 6/17/2022. (kmd) |
| Jun 17, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Brandon M. White for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Jun 16, 2022 | 14 | Motion for Leave to Appear Pro Hac Vice (6) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Brandon M. White, Shannon M. Bloodworth, Emily J. Greb and Maria A. Stubbings of Perkins Coie LLP - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) |
| Jun 16, 2022 | 15 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Viatris Inc.. (Cottrell, Frederick) |
| Jun 16, 2022 | 16 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan Inc., Other Affiliate Viatris Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc.. (Cottrell, Frederick) |
| Jun 16, 2022 | 17 | Main Document (2) Docket Text: MOTION to Dismiss for Improper Venue - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # (1) Text of Proposed Order)(Cottrell, Frederick) |
| Jun 16, 2022 | 17 | Text of Proposed Order (1) |
| Jun 16, 2022 | 18 | Main Document (28) Docket Text: OPENING BRIEF in Support re [17] MOTION to Dismiss for Improper Venue filed by Mylan Pharmaceuticals Inc., Viatris Inc..Answering Brief/Response due date per Local Rules is 6/30/2022. (Attachments: # (1) Certificate of Compliance)(Cottrell, Frederick) |
| Jun 16, 2022 | 18 | Certificate of Compliance (1) |
| Jun 16, 2022 | 19 | Main Document (8) Docket Text: DECLARATION re [18] Opening Brief in Support, [Keith Meckstroth] by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # (1) Exhibit A)(Cottrell, Frederick) |
| Jun 16, 2022 | 19 | Exhibit A (8) |
| Jun 16, 2022 | 20 | Main Document (2) Docket Text: DECLARATION re [18] Opening Brief in Support, [Maria A. Stubbings] by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2)(Cottrell, Frederick) |
| Jun 16, 2022 | 20 | Exhibit 1 (2) |
| Jun 16, 2022 | 20 | Exhibit 2 (6) |
| Jun 10, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [13] STIPULATION TO EXTEND TIME to move, answer or otherwise respond to the Complaint to and including June 16, 2022, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Reset Answer Deadlines: Mylan Pharmaceuticals Inc. answer due 6/16/2022; Viatris Inc. answer due 6/16/2022. Ordered by Judge Colm F. Connolly on 6/10/2022. (kmd) |
| Jun 10, 2022 | 13 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to move, answer or otherwise respond to the Complaint to and including June 16, 2022 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) |
| Jun 2, 2022 | 10 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Frederick L. Cottrell, III on behalf of Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Cottrell, Frederick) |
| Jun 2, 2022 | 11 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Christine Dealy Haynes on behalf of Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Haynes, Christine) |
| Jun 2, 2022 | 12 | Notice (Other) (3) Docket Text: NOTICE of Withdrawal of Appearance by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. of Ian R. Liston (Liston, Ian) |
| May 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [9] STIPULATION TO EXTEND TIME to Answer, Move or Otherwise Respond to Complaint to June 10, 2022, filed by Viatris Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Reset Answer Deadlines: Mylan Pharmaceuticals Inc. answer due 6/10/2022; Viatris Inc. answer due 6/10/2022. Ordered by Judge Colm F. Connolly on 5/11/2022. (kmd) |
| May 11, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Party text for DI [9] has been modified per counsel's request. (mpb) |
| May 10, 2022 | 9 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to Answer, Move or Otherwise Respond to Complaint to June 10, 2022 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Liston, Ian) Modified on 5/11/2022 (mpb). |
| Apr 20, 2022 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. Viatris Inc. served on 4/20/2022, answer due 5/11/2022. (Mayo, Andrew) |
| Apr 20, 2022 | 8 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. Mylan Pharmaceuticals Inc. served on 4/20/2022, answer due 5/11/2022. (Mayo, Andrew) |
| Apr 13, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Apr 8, 2022 | 1 | Main Document (38) Docket Text: COMPLAINT FOR PATENT INFRINGEMENT - filed against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3847462.) - filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. (Attachments: # (1) Exhibit A-M, # (2) Civil Cover Sheet)(mal) |
| Apr 8, 2022 | 1 | Exhibit A-M (210) |
| Apr 8, 2022 | 1 | Civil Cover Sheet (3) |
| Apr 8, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Apr 8, 2022 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 02/24/2022. Date of Expiration of Patent: see attached.Thirty Month Stay Deadline: 8/24/2024. (mal) |
| Apr 8, 2022 | 4 | Patent/Trademark Report to Commissioner (2) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) see attached. (mal) |
| Apr 8, 2022 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Otsuka Pharmaceutical Co., Ltd. filed by Otsuka Pharmaceutical Co., Ltd.. (mal) |
| Apr 8, 2022 | 6 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by H. Lundbeck A/S. (mal) |
| Apr 8, 2022 | 1 | Complaint* (1) |
